Mechanistic insights into bismuth(<scp>iii</scp>) inhibition of SARS-CoV-2 helicase

Wei, Xueying; Chan, Chun-Lung; Zhou, Ying; Tang, Kaiming; Chen, Jingxin; Wang, Suyu; Chan, Jasper Fuk-Woo; Yuan, Shuofeng; Li, Hongyan; Sun, Hongzhe

doi:10.1039/d3sc06961c

Chem. Sci.

2024

DOI: 10.1039/d3sc06961c

|View full text |Cite

Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase

Xueying Wei,

Chun-Lung Chan,

Ying Zhou

et al.

Abstract: Helicase(nsp13) is an important target of bismuth-based antivirals by metal-tagged antibody-based approach.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

International Drug Repurposing Patent Landscaping, Part 2: The Early Months of Covid-19

Mucke

2024

Drug Repurposing

View full text Add to dashboard Cite

This study presents and discusses international patent applications claiming known pharmaceutical agents for repurposed use in the treatment of coronavirus disease 2019 (Covid-19). These applications were published by the World Intellectual Property Office during the second half of 2021, corresponding to filings made during the first 6 months of the pandemic (January to June 2020). Of the 93 identified documents, 46 claimed agents that were in development, or had been approved, as antiparasitics, antibiotics, anticancer agents, or immunomodulators. The remaining 47 documents concerned a wide variety of other original uses, from psychiatry to osteoporosis, and correspondingly diverse mechanisms of action. The most significant patent applications are presented and discussed in brief. The landscape of patent applications seeking to repurpose pharmaceutical agents for use in the treatment of Covid-19, filed during the early stages of the pandemic, is impressive. It provides insight into the intellectual property track pursued by industry, academia, and government organizations during this unique period.

show abstract

International Drug Repurposing Patent Landscaping, Part 2: The Early Months of Covid-19

Mucke

2024

Drug Repurposing

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase

Abstract: Helicase(nsp13) is an important target of bismuth-based antivirals by metal-tagged antibody-based approach.

Cited by 1 publication

References 46 publications

International Drug Repurposing Patent Landscaping, Part 2: The Early Months of Covid-19

International Drug Repurposing Patent Landscaping, Part 2: The Early Months of Covid-19

Contact Info

Product

Resources

About